FDA's rocket docket

FDA is approving more cancer drugs, more rapidly than ever, and the trend is likely to continue, according to Richard Pazdur, director of the Office of Hematology and Oncology Drug Products at FDA's Center for Drug Evaluation and Research.

In an interview with BioCentury TV, Pazdur said unprecedented efficacy in early stage trials is prompting the agency to review cancer drug applications as quickly as possible, to approve cancer drugs based on single-arm and early stage trials, and to streamline review procedures for supplemental indications...